Interstitial cystitis: A pathophysiology and treatment update

Clinical Obstetrics and Gynecology

Volumn 45, Issue 1, 2002, Pages 259-272

  Moldwin, Robert M ^a   Sant, Grannum R ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BCG VACCINE; BELLADONNA ALKALOID; BUPIVACAINE; CAPSAICIN; CARBAMAZEPINE; CIMETIDINE; CYSTISTAT; DIMETHYL SULFOXIDE; GABAPENTIN; GENTAMICIN; HEPARIN; HYALURONIC ACID; HYDROXYZINE; HYDROXYZINE EMBONATE; LIDOCAINE; NARCOTIC AGENT; OXYCHLOROSENE; PAROXETINE; PENTOSAN POLYSULFATE; RESINIFERATOXIN; SEROTONIN UPTAKE INHIBITOR; SILVER NITRATE; TRIAMCINOLONE; VENLAFAXINE; WCS 90;

AUTOIMMUNITY; BLADDER DISTENSION; BLADDER EPITHELIUM; BONE MARROW SUPPRESSION; CONFERENCE PAPER; CONSTIPATION; CYSTECTOMY; DIET RESTRICTION; DISEASE EXACERBATION; DYSPEPSIA; FATIGUE; HEART PALPITATION; HUMAN; INFECTION; INFLAMMATION; INTERSTITIAL CYSTITIS; LASER SURGERY; LIVER TOXICITY; MAST CELL; NEUROGENIC BLADDER; NEUROMODULATION; PATHOPHYSIOLOGY; RESPIRATION DEPRESSION; SELF CARE; SEXUAL DYSFUNCTION; TREATMENT PLANNING; URINALYSIS; URINARY DIVERSION; URINE RETENTION; URTICARIA; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; AMITRIPTYLINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AUTOIMMUNITY; CAPSAICIN; CYSTECTOMY; CYSTITIS, INTERSTITIAL; DIMETHYL SULFOXIDE; HUMANS; PENTOSAN SULFURIC POLYESTER; SOLVENTS; URINARY DIVERSION; URODYNAMICS;

EID: 0036193697     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200203000-00027     Document Type: Conference Paper

References (94)

1. Treatment used in women with interstitial cystitis: The Interstitial Cystitis Data Base (ICDB) study experience
2. Electron microscopic investigation of the bladder urothelium and glycocalyx in interstitial cystitis
3. The bladder mucus (glycosaminoglycan) layer in interstitial cystitis
4. Scanning electron microscopic findings in interstitial cystitis
5. Decreased expression of a glycoproteins component of bladder surface mucin (GP1) in interstitial cystitis
6. Bladder surface glycosaminoglycans (GAGs) in interstitial cystitis
7. Bladder surface glycosaminoglycans is a human epithelial permeability factor
8. Decreased expression of GP-51 glycosaminoglycan in cats afflicted with feline interstitial cystitis
9. Excretion of fluorescein in the urine of women with interstitial cystitis
10. Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease
11. 99mtechnetium-diethylenetriaminepentaacetic acid
12. Protamine sulfate-induced cystitis: A model of selective cytodestruction of the urothelium
13. Interstitial cystitis as an infectious disease
14. Evidence for a mechanism of bacterial toxin action that may lead to the onset of urothelial injury in the interstitial cystitis bladder
15. Interstitial cystitis: Increased sympathetic innervation and related neuropeptide synthesis
16. Increased number of substance P positive fibers in interstitial cystitis
17. Urinary substance P is elevated in women with interstitial cystitis
18. Interstitial cystitis: A critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis
19. Bladder mast cell activation in interstitial cystitis
20. Agents that release histamine from mast cells
21. Stress-induced bladder mast cell activation: Implications for interstitial cystitis
22. Increased mast cells of bladder in suspected cases of interstitial cystitis: Possible disease marker
23. Mast cell involvement in interstitial cystitis
24. Mast cell involvement in interstitial cystitis: A review of human and experimental evidence
25. Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis
26. Increased urine histamine and methylhistamine in interstitial cystitis
27. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis
28. Interstitial cystitis is associated with intraurothelial Tamm-Horsfall protein
29. Role of toxic urine in interstitial cystitis
30. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis
31. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production
32. A diagnostic in vitro urine assay for interstitial cystitis
33. Role of toxic urine in interstitial cystitis
34. Oral methotexate in the management of refractory interstitial cystitis
35. Bladder antibodies in interstitial cystitis
36. Antitissue autoantibodies in interstitial cystitis
37. The enigma of interstitial cystitis- An autoimmune disease?
38. Interstitial cystitis: A critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis
39. Interstitial cystitis: Successful management by increasing urinary voiding intervals
40. Successful therapy of interstitial cystitis with pentosan-polysulfate
41. A prospective double-blind clinically controlled multicenter trial of sodium pentosan polysulfate in the treatment of interstitial cystitis
42. Pentosan polysulfate sodium for therapy of interstitial cystitis
43. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosan polysulfate
44. Interstitial cystitis: Update on etiologies and therapeutic options
45. Safety and efficacy of up to 900 mg/day polysulfate sodium (Elmiron) in patients with interstitial cystitis
46. Amitriptyline in the treatment of interstitial cystitis
47. Use of amitriptyline in the treatment of interstitial cystitis
48. Use of Amitriptyline in interstitial cystitis
49. Conservative therapy of interstitial cystitis
50. Hydroxyzine therapy for interstitial cystitis
51. Pelvic floor dysfunction in interstitial cystitis
52. Cimetidine in the treatment of interstitial cystitis
53. Cimetidine in the treatment of interstital cystitis
54. Neuropathic pain syndromes
55. Addiction rare in patients treated with narcotics
56. Long-term use of opoids in chronic pain patients with nonterminal disease states
57. Chronic use of opioid analgesics in nonmalignant pain: Report of 38 cases
58. Dimethyl sulfoxide (DSMO): A new concept in pharmacotherapy
59. Pharmacology of DMSO
60. The use of dimethylsulfoxide (DMSO) in the treatment of interstitial cystitis
61. Urinary Substance P Concentration Correlates with Urinary Frequency and Urgency in Interstitial Cystitis Patients Treated with DMSO and Not Anesthetic Cocktail
62. Intravesical 50% dimethylsulfoxide (Rimso-50) in the treatment of interstitial cystitis
63. DMSO: Effect on bladder afferent neurons and nitric oxide release
64. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy
65. Recent concepts of interstitial cystitis
66. Treatment of interstitial cystitis with intravesical heparin
67. Epithelial coating techniques in the treatment of interstitial cystitis
68. Interstitial cystitis: Treatment with silver nitrate
69. Interstitial cystitis: Experience and review of recent literature
70. Interstitial cystitis: Treatment with Clorpactin WCS 90
71. Complication of Clorpactin WCS 90 therapy for interstitial cystitis
72. The efficacy of intravesical bacillus Calmette-Guérin in the treatment of interstitial cystitis: Long-term followup
73. Intravesical bacillus Calmette-Guérin and dimethlysulfoxide for treatment of classic and nonulcer interstitial cystitis: A prospective, randomized double-blind study
74. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis
75. Cystistat for the treatment of interstitial cystitis: A 3-year follow-up study
76. Urodynamic effects of intravesical resiniferatoxin in humans: Preliminary results in stable and unstable detrusor
77. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlled study
78. Intravesical capsaicin for the treatment of severe bladder pain: A randomized, placebo controlled study
79. Densensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction
80. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlleed study
81. Increased production of bladder surface mucin due to bladder trauma
82. The use of the Nd:YAG laser in the management of interstitial cystitis
83. Laser therapy for interstitial cystitis
84. Sacral nerve root neeuromodulation: An effective treatment for regractory urge incontinence
85. Sacral nerve stimulation in patients with chronic intractable pelvic pain
86. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalized urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis
87. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis
88. Complementary approaches in the management of interstitial cystitis
89. Electric stimulation in the management of interstitial cystitis
90. Nonbladder related symptoms in patients with interstitial cystitis
91. Interstitial cystitis: Unexplained associations with other chronic disease and pain syndromes